PE firm founded in 2015 and is based in Beijing, China has approximately $100M assets under management and manages 2 active funds – the RMB and USD Funds – that focus on investments in the life science space. The RMB Fund invests $5-40 M in companies based in China, and the USD Fund invests $5-10 M in companies of all parts of the world, with a focus in US and China. With these funds, the firm will make 1-2 investments per year in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.
The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and healthcare IT. The firm will not consider companies with pre-clinical or early clinical assets. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.
The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org